Literature DB >> 31889921

Evaluating the predictive value of quantec rectum tolerance dose suggestions on acute rectal toxicity in prostate carcinoma patients treated with IMRT.

E Elif Ozkan1, Alper Ozseven1, Z Arda Kaymak Cerkesli1.   

Abstract

AIM: To investigate the predictive value of convenience of rectum dosimetry with Quantitative Analysis of Normal Tissue Effects in the Clinic (QUANTEC) dose limits, maximum rectum dose (Dmax), total rectal volume (TVrectum), rectal volume included in PTV (VrectumPTV) on Grade 2-3 acute rectal toxicity for utilization in clinical practice.
BACKGROUND: Numerous previous data have reported frequent acute proctitis after external-beam RT of prostate cancer. Predicting toxicity limited with dose information is inadequate in clinical practice due to comorbidities and medications used. MATERIALS AND
METHOD: Sixty-four non-metastatic prostate cancer patients treated with IMRT were enrolled. Patients were treated to a total dose of 70-76 Gy. Rectal dose volume histograms (DVH) of all patients were evaluated retrospectively, and a QUANTEC Score between 0 and 5 was calculated for each patient. The correlation between the rectal DVH data, QUANTEC score, TVrectum, VrectumPTV, rectum Dmax and Grade 2-3 rectal toxicity was investigated.
RESULTS: In the whole group grade 1, 2 and 3 acute rectal toxicities were 25%, 18.8% and 3.1%, respectively. In the DVH data, rectum doses of all patients were under RTOG dose limits. Statistically significant correlation was found between grade 2-3 rectal toxicity and TVrectum (p = 0,043); however. It was not correlated with QUANTEC score, VrectumPTV and Dmax.
CONCLUSION: Our results were not able to show any significant correlation between increasing convenience with QUANTEC limits and lower rectal toxicity. Conclusively, new dosimetric definitions are warranted to predict acute rectal toxicity more accurately in prostate cancer patients during IMRT treatment.
© 2019 Greater Poland Cancer Centre. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acute rectal toxicity; Prostate cancer; Radiotherapy

Year:  2019        PMID: 31889921      PMCID: PMC6931199          DOI: 10.1016/j.rpor.2019.12.002

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  64 in total

1.  Two formulas for computation of the area under the curve represent measures of total hormone concentration versus time-dependent change.

Authors:  Jens C Pruessner; Clemens Kirschbaum; Gunther Meinlschmid; Dirk H Hellhammer
Journal:  Psychoneuroendocrinology       Date:  2003-10       Impact factor: 4.905

2.  Treatment of T3 and T4 anal carcinoma with combined chemoradiation and interstitial 192Ir implantation: a 10-year experience.

Authors:  Julie M Hwang; Aroor R Rao; Harry A Cosmatos; Ricardo Wang; John S Kaptein; Robert A Kagan; Jim Y Hsiang; Michael Tome
Journal:  Brachytherapy       Date:  2004       Impact factor: 2.362

3.  Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)

Authors:  J D Cox; J Stetz; T F Pajak
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-03-30       Impact factor: 7.038

4.  RTOG Late Effects Working Group. Overview. Late Effects of Normal Tissues (LENT) scoring system.

Authors:  P Rubin; L S Constine; L F Fajardo; T L Phillips; T H Wasserman
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-03-30       Impact factor: 7.038

5.  Endoscopic scoring of late rectal mucosal damage after conformal radiotherapy for prostatic carcinoma.

Authors:  S Wachter; N Gerstner; G Goldner; R Pötzi; A Wambersie; R Pötter
Journal:  Radiother Oncol       Date:  2000-01       Impact factor: 6.280

6.  Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer.

Authors:  Michael J Zelefsky; Heather Chan; Margie Hunt; Yoshiya Yamada; Alison M Shippy; Howard Amols
Journal:  J Urol       Date:  2006-10       Impact factor: 7.450

7.  Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial.

Authors:  Alan Pollack; Gunar K Zagars; George Starkschall; John A Antolak; J Jack Lee; Eugene Huang; Andrew C von Eschenbach; Deborah A Kuban; Isaac Rosen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-08-01       Impact factor: 7.038

8.  Assessing correlations between the spatial distribution of the dose to the rectal wall and late rectal toxicity after prostate radiotherapy: an analysis of data from the MRC RT01 trial (ISRCTN 47772397).

Authors:  Florian Buettner; Sarah L Gulliford; Steve Webb; Matthew R Sydes; David P Dearnaley; Mike Partridge
Journal:  Phys Med Biol       Date:  2009-10-14       Impact factor: 3.609

9.  Association between rectal bleeding and the absolute dose volume of the rectum following image-guided radiotherapy for patients with prostate cancer.

Authors:  Kazuki Kotabe; Hidetsugu Nakayama; Aruga Takashi; Atsuko Takahashi; Tsuyoshi Tajima; Haruki Kume
Journal:  Oncol Lett       Date:  2018-06-04       Impact factor: 2.967

10.  Dose-volume relationships for acute bowel toxicity in patients treated with pelvic nodal irradiation for prostate cancer.

Authors:  Claudio Fiorino; Filippo Alongi; Lucia Perna; Sara Broggi; Giovanni Mauro Cattaneo; Cesare Cozzarini; Nadia Di Muzio; Ferruccio Fazio; Riccardo Calandrino
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-05-19       Impact factor: 7.038

View more
  2 in total

Review 1.  A Ten-year-long Update on Radiation Proctitis Among Prostate Cancer Patients Treated With Curative External Beam Radiotherapy.

Authors:  Gianluca Ferini; Stefano Pergolizzi
Journal:  In Vivo       Date:  2021-04-28       Impact factor: 2.406

2.  Effect of intensity-modulated radiation therapy on sciatic nerve injury caused by echinococcosis.

Authors:  Wan-Long Xu; Dilimulati Aikeremu; Jun-Gang Sun; Yan-Jun Zhang; Jiang-Bo Xu; Wen-Zheng Zhou; Xi-Bin Zhao; Hao Wang; Hong Yuan
Journal:  Neural Regen Res       Date:  2021-03       Impact factor: 5.135

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.